AUTHOR=Wang Xiaochun , Batty Kathleen M. , Crowe Philip J. , Goldstein David , Yang Jia-Lin 

TITLE=The Potential of panHER Inhibition in Cancer

JOURNAL=Frontiers in Oncology

VOLUME=5

YEAR=2015

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2015.00002

DOI=10.3389/fonc.2015.00002

ISSN=2234-943X

ABSTRACT=<p><bold>Purpose:</bold> Hyper-activation of the HER (erbB) family receptors, HER 1-4, leads to up-regulation of the three vital signaling pathways: mitogen activated protein kinase, phosphoinositide 3-kinase/AKT, and Janus kinase/signal transducer and activator of transcription pathways. Blocking HER1/EGFR has a limited anticancer effect due to either secondary mutation e.g., T790M or by-pass signaling of other HER members. The emergence of an anti-panHER approach to blockade of these pathways as a cancer treatment may provide a solution to this resistance. This review aimed to provide an overview of the HER signaling pathways and their involvement in tumor progression and examine the current progress in panHER inhibition.</p><p><bold>Methods:</bold> Recent literature associated with HER signaling pathways and panHER inhibition was reviewed through PubMed and Medline database, followed by critical comparison and analysis.</p><p><bold>Results:</bold> Pre-clinical studies and clinical trials of panHER inhibitors show promising results, and the potential to improve patient outcomes in solid cancers.</p><p><bold>Conclusion:</bold> The use of panHER inhibitors in cancers with HER-family hyper-activation, such as other epithelial cancers and sarcoma, is a new direction to research and has potential in clinical cancer therapy in the future.</p>